Thermo Fisher Scientific filings document operating results, material agreements, governance matters and capital-structure disclosures for a global supplier of scientific instruments, laboratory products, diagnostics, life science tools and pharmaceutical services. Recent Form 8-K reports include quarterly and annual results, acquisition-related events and definitive agreements.
The company’s proxy materials cover shareholder voting and board-governance matters. Its securities disclosures identify common stock and multiple NYSE-listed senior note classes, while Form 25 filings document removal from listing and registration for specific senior notes. The filing record also includes risk-factor and corporate disclosure categories tied to Thermo Fisher’s operating businesses and financing structure.
Thermo Fisher Scientific has completed its acquisition of Clario Holdings, Inc., a provider of endpoint data solutions for clinical trials, for $8.875 billion in cash, plus potential additional earn-out and other performance-based payments. The deal also includes a further $125 million payment due in January 2027 and up to $400 million of earn-out payments tied to Clario’s results in 2026 and 2027.
Clario will join Thermo Fisher’s Laboratory Products and Biopharma Services segment, enhancing its clinical research data capabilities. Thermo Fisher expects the transaction to generate a double-digit internal rate of return, be accretive to adjusted operating margin, add $0.45 of adjusted EPS in the first year after close, and deliver about $175 million of adjusted operating income synergies by year five.
Thermo Fisher Scientific Executive Vice President Michael D. Shafer sold 1,607 shares of common stock in an open-market transaction. The sale occurred at a price of $499.40 per share, and followed a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025.
After this transaction, Shafer directly holds 20,949.9546 Thermo Fisher Scientific shares. Because the trade was executed under a Rule 10b5-1 plan, its timing reflects a preset schedule rather than a discretionary market-timing decision.
Thermo Fisher Scientific Inc. senior vice president and CFO James Meyer filed an initial ownership statement reporting his equity stake in the company. The filing shows direct ownership of 5,841.4637 shares of common stock and an additional 50.03 shares held indirectly through a 401(k) plan.
He also reports multiple stock option awards on Thermo Fisher common stock with exercise prices ranging from 430.7300 to 635.1000 per share and expiration dates between 2028 and 2035. Individual grants include, for example, 6,851 underlying shares at an exercise price of 513.6800 and 3,598 underlying shares at an exercise price of 430.7300, reflecting substantial unexercised option-based exposure.
Thermo Fisher Scientific Chairman & CEO Marc N. Casper exercised stock options for 4,000 shares of common stock and reported related trades in Thermo Fisher Scientific Inc. stock. The option exercise, at an exercise price of $0.00 per share, converted into 4,000 shares of common stock.
On the same date, he sold 4,000 shares of common stock in a series of open-market transactions at prices ranging from $503.66 to $519.74, pursuant to a Rule 10b5-1 trading plan adopted on November 11, 2025. Following these transactions, he directly held 125,360.358 shares of common stock.
Additional shares are held indirectly by the Alison Casper 2020 Irrevocable Trust (11,300 shares), Floral Park Associates, Inc. (14,608 shares) and the MNC 2020 Irrevocable Trust (5,000 shares, all as of the reported date), with Casper disclaiming beneficial ownership of these indirect holdings except to the extent of any pecuniary interest.
Thermo Fisher Scientific Inc. Chairman & CEO Marc N. Casper reported option exercises and related share sales in company stock. On March 3 and 4, 2026, he exercised stock options for a total of 10,000 shares of Common Stock at a reported exercise price of $309.63 per share in multiple transactions coded as derivative exercises.
Over the same two days, Casper sold 10,000 shares of Common Stock in a series of open-market transactions, with prices reported around $495.29–$517.05 per share as weighted-average prices across multiple trades. The transactions were effected under a Rule 10b5-1 trading plan adopted on November 11, 2025. Following these transactions, he directly held 123,925.358 shares of Common Stock and 44,550 stock options. Additional shares are held indirectly through the Alison Casper 2020 Irrevocable Trust, the MNC 2020 Irrevocable Trust, and Floral Park Associates, Inc., for which he disclaims beneficial ownership except for any pecuniary interest.
TMO files a Rule 144 notice reporting a proposed cash sale of 4,000 common shares on 03/05/2026.
The filing lists the securities as options granted on 02/25/2020 and identifies the sale method as cash. The excerpt also shows prior reported sales by Marc N. Casper: 5,000 shares on 03/03/2026 and 5,000 shares on 03/04/2026.
Marc Casper reported the sale of 5,000 common shares of TMO. The filing shows a sale dated 03/03/2026 with aggregate proceeds of $2,507,550.00 and a separate planned sale entry of 5,000 shares on 03/04/2026 tied to an option granted 02/25/2020.
Brokerage details list Fidelity Brokerage Services LLC and the transaction type is listed as Cash. The filing is a Form 144 disclosure of insider sales under the issuer symbol TMO.
Filer submitted a Form 144 notice to sell Common stock of the issuer (symbol TMO). The filing lists multiple restricted stock vesting lots and share counts by vesting date, including 980 shares vesting 02/23/2024, 955 shares vesting 02/28/2024, and other lots of 776, 705, 577, 434, 389, 233, 123, and 52 shares on various dates. The listed broker is Fidelity Brokerage Services LLC.